The molecular basis of haemophilia B

Haemophilia

Volumn 4, Issue 4, 1998, Pages 350-357

  Lillicrap, D ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Factor IX; Genetics; Haemophilia B; Molecular biology

Indexed keywords

BLOOD CLOTTING FACTOR 9;

CONFERENCE PAPER; GENE ISOLATION; GENE MUTATION; HEMOPHILIA B; HUMAN; INTERNET; MOLECULAR BIOLOGY; MOLECULAR CLONING; PRIORITY JOURNAL;

EID: 0031858612     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440350.x     Document Type: Conference Paper

References (71)

1. Sommer SS, Ketterling RP. The factor IX gene as a model for analysis of human germline mutations: an update. Hum Mol Genet 1996; 5: 1505-14.
2. Kurachi K, Kurachi S. Regulatory mechanism of the factor IX gene. Thromb Haemost 1995; 73: 333-9.
3. High KA, Roberts HR. Factor IX. In: High KA, Roberts HR, eds. Molecular Basis of Thrombosis and Hemostasis. New York: Marcel Dekker, 1995; 215-38.
4. Haldane JBS, Smith CAB. A new estimate of the linkage between the genes for colour blindness and haemophilia in man. Ann Eugen 1947; 14: 10-31.
5. Koller. Ueber eine besondere form hamorrhagischer diathese. Schweizerischen medizinischen Wochenschrift 1950; 80: 1101-20.
6. Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey C, O'Brien JR. Christmas disease: a condition previously mistaken for haemophilia. Br Med J 1952; 2: 1378-82.
7. Walker I, Pai M, Akabutu J, Ritchie B, Growe G, Poon MC, Card R, et al. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995; 35: 548-51.
8. Pechet L, Tiarks CY, Stevens J, Sudhindra RR, Lipworth L. Relationship of factor IX antigen and coagulant in haemophilia B patients and carriers. Thromb Haemost 1978; 40: 465-77.
9. Kurachi K, Davie EW. Isolation and characterisation of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 1982; 79: 6461-4.
10. Choo KH, Gould KG, Rees DJG, Brownlee GG. Molecular cloning of the gene for human anti-haemophilia factor IX. Nature 1982; 299: 178-80.
11. Pai GS, Sprenkle JA, Do TT, Mareni CE, Migeon BR. Localization of loci for hypoxanthine phosphoribosyltransferase and glucose-6-phosphate dehydrogenase and biochemical evidence of nonrandom X chromosome expression from studies of a human X-autosome translocation. Proc Natl Acad Sci USA 1980; 77: 2810-13.
12. Mueller OT, Hartsfield JK, Jr., Gallardo LA, Essig YP, Miller KL, Papenhausen PR, Tedesco TA. Low oculocerebrorenal syndrome in a female with a balanced X;20 translocation: mapping of the X chromosome breakpoint. Am J Hum Genet 1991; 49: 804-10.
13. Anson DS, Blake DJ, Winship PR, Birnbaum D, Brownlee GG. Nullisomic deletion of the mcf.2 transforming gene in two haemophilia B patients. EMBO J 1988; 7: 2795-9.
14. Anson DS, Choo KH, Rees DJG, Giannelli F, Gould K, Huddleston JA, Brownlee GG. The gene stucture of human anti-haemophilic factor IX. EMBO J 1984; 3: 1053-60.
15. Reijnen MJ, Bertina RM, Reitsma PH. Localization of transcription initiation sites in the human coagulation factor IX gene. FEBS Let 1990; 270: 207-10.
16. Kurachi S, Furukawa M, Salier JP, Wu CT, Wilson EJ, French FS, Kurachi K. Regulatory mechanism of human factor IX gene: protein binding at the Leyden-specific region. Biochemistry 1994; 33: 1580-91.
17. Galeffi P, Brownlee GG. The propeptide region of clotting Factor DC is a signal for a vitamin K dependent carboxylase: evidence from protein engineering of amino acid -4. Nucleic Acids Res 1987; 15: 9505-13.
18. Handford PA, Baron M, Mayhew M, Willis A, Beesley T, Brownlee GG, Campbell ID. The first EGF-like domain from human factor IX contains a high-affinity calcium binding site. EMBO J 1990; 9: 475-80.
19. Ahmad SS, Rawala R, Cheung WF, Stafford DW, Walsh PN. The role of the second growth-factor domain of human factor IXa in binding to platelets and in factor-X activation. Biochem J 1995; 310: 427-31.
20. Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi W. Nucleotide sequence of the gene for human factor IX (antihaemophilic factor B). Biochem J 1985; 24: 3736-50.
21. Giannelli F, Choo KH, Winship PR. Characterisation and use of an intragenic polymorphic marker for detection of carriers of haemophilia B (factor IX deficiency). Lancet 1984; 1: 239-41.
22. Winship PR, Anson DS, Rizza CR, Brownlee GG. Carrier detection in haemophilia B using two further intragenic restriction fragment length polymorphisms. Nucleic Acids Res 1984; 12: 8861-8.
23. Hay CW, Robertson KA, Yong SL, Thompson AR, Growe GH, MacGillivray RTA. Use of a BamHI polymorphism in the factor IX gene for the determination of haemophilia B carrier status. Blood 1986; 67: 1508-11.
24. Winship PR, Nichols CE, Chuansumrit A, Peake IR. An Msel RFLP in the 5′ flanking region of the factor IX gene: Its use for haemophilia B carrier detection in Caucasian and Thai populations. Br J Haematol 1993; 84: 101-5.
25. McGraw RA, Davis LM, Noyes CM, Lundblat RL, Roberts HR, Graham JB, Nedellec J. Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX. Proc Natl Acad Sci USA 1985; 82: 2847-51.
26. Peake I. Registry of DNA polymorphisms within or close to the human factor VIII and factor IX genes - For the Factor VIII/IX Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1992; 67: 277-80.
27. Peake IR, Lillicrap DP, Boulyjenkov V, Briet E, Chan V, Ginter EK, Kraus EM, et al. Haemophilia: strategies for carrier detection and prenatal diagnosis. Bulletin of the World Health Organization 1993; 71: 429-58.
28. Graham JB, Kunkel GR, Egilmez NK, Wallmark A, Fowlkes DM, Lord ST. The varying frequencies of five DNA polymorphisms of X-linked coagulant factor IX in eight ethnic groups. Am J Hum Genet 1991; 49: 537-44.
29. Chan V, Yip B, Tong TMF, Chan TPT, Lau K, Yam I, Chan TK. Molecular defects in haemophilia B: Detection by direct restriction enzyme analysis. Br J Haematol 1991; 79: 63-9.
30. Montandon AJ, Green PM, Giannelli F, Bentley DR. Direct detection of point mutations by mismatch analysis: application to haemophilia B. Nucleic Acids Res 1989; 17: 3347-58.
31. Stoflet ES, Koeberl DD, Sarkar G, Sommer SS. Genomic amplification with transcript sequencing. Science 1988; 239: 491-5.
32. Bristol JA, Furie BC, Furie B. Propeptide processing during factor DC biosynthesis. Effect of point mutations adjacent to the propeptide cleavage site. J Biol Chem 1993; 268: 7577-84.
33. val-397. J Biol Chem 1991; 266: 15213-20.
34. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-6.
35. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 5804-9.
36. Giannelli F, Green PM, High KA, Lozier JN, Lillicrap DP, Ludwig M, Olek K, et al. Haemophilia B: Database of point mutations and short additions and deletions. Nucleic Acids Res 1990; 18: 4053-4059.
37. Giannelli F, Green PM, Sommer SS, Poon MC, Ludwig M, Schwaab R, Reitsma PH, et al. Haemophilia B: database of point mutations and short additions and deletions, 7th edition. Nucleic Acids Res 1997; 25: 133-5.
38. Thompson AR, Bajaj SP, Chen S-H, MacGillivray RTA. "Founder" effect in different families with haemophilia B mutation. Lancet 1990; 335: 418.
39. - A factor IX promoter mutation is the result both of a founder effect and recurrent mutation at a CpG dinucleotide. Br J Haematol 1995; 89: 672-4.
40. - C:G transversions at CpG dinucleotides in the human factor IX gene. Am J Hum Genet 1994; 54: 831-5.
41. High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. Adv Exp Med Biol 1995; 386: 79-86.
42. Montandon AJ, Green PM, Bentley DR, Ljung R, Kling S, Nilsson IM, Giannelli F. Direct estimate of the haemophilia B (factor DC deficiency) mutation rate and of the ratio of the sex-specific mutation rates in Sweden. Hum Genet 1992; 89: 319-22.
43. Kling S, Ljung R, Sjorin E, Montandon J, Green P, Giannelli F, Nilsson IM. Origin of mutation in sporadic cases of haemophilia-B. Eur J Haematol 1992; 48: 142-5.
44. Taylor SAM, Deugau KV, Lillicrap DP. Somatic mosaicism and female to female transmission in a kindred with hemophilia B (factor IX deficiency). Proc Natl Acad Sci USA 1991; 88: 39-42.
45. Briet E, Bertina RM, Van Tilburg NH, Veltkamp JJ. Hemophilia B Leyden: A sex linked hereditary disorder that improves after puberty. N Engl J Med 1982; 306: 788-92.
46. Sweeney JD, Hoernig LA. Age-dependent effect on the level of factor IX. Am J Clin Pathol 1993; 99: 687-8.
47. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
48. Simpson NE, Biggs R. The inheritance of Christmas factor. Br J Haematol. 1962; 8: 191-203.
49. Crossley M, Brownlee GG. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature 1990; 345: 444-6.
50. Reijnen MJ, Sladek FM, Bertina RM, Reitsma PH. Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden. Proc Natl Acad Sci USA 1992; 89: 6300-3.
51. Naka H, Brownlee GG. Transcriptional regulation of the human factor IX promoter by the orphan receptor super-family factor, HNF4, ARP1 and COUP/Ear3. Br J Haematol 1996; 92: 231-40.
52. Vidaud D, Tartary M, Costa J-M, Bahnak BR, GispertSanchez S, Fressinaud E, Gazengel C, et al. Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: Consequences for genetic counseling. Hum Genet 1993; 91: 241-4.
53. Briet E, Wijnands MC, Veltkamp JJ. The prophylactic treatment of hemophilia B Leyden with anabolic steroids. Ann Int Med 1985; 103:225-6.
54. Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: An androgen-responsive element in the factor IX promoter. Science 1992; 257: 377-9.
55. Morgan GE, Rowley G, Green PM, Chisholm M, Giannelli F, Brownlee GG. Further evidence for the importance of an androgen response element in the factor IX promoter. Br J Haematol 1997; 98: 79-85.
56. Picketts DJ, Lillicrap DP, Mueller CR. Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation. Nature Genet 1993; 3: 175-9.
57. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA 1995; 92: 9796-800.
58. Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996; 98: 1619-25.
59. Oldenburg J, Quenzel EM, Harbrecht U, Fregin A, Kress W, Muller CR, Hertfelder HJ, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-4.
60. Hoyer LW. Factor VIII inhibitors: A continuing problem. J Lab Clin Med 1993; 121: 385-7.
61. Biggs R. Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom. Br J Haematol 1974; 26: 313-29.
62. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 1992; 67: 600-2.
63. Briet E. Factor IX inhibitors in haemophilia B patients: their incidence and prospects for development with high purity factor IX products. Blood Coag Fibrin 1991; 2: 47-50.
64. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4.
65. Rosendaal FR, Nieuwenhuis HK, Van den Berg HM, Heijboer H, Mauser-Bunschoten EP, Van der Meer J, Smit C, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81: 2180-6.
66. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-59.
67. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
68. Giannelli F, Choo KH, Rees DJG, Boyd Y, Rizza CR, Brownlee GG. Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature 1983; 303: 181-2.
69. Matthews RJ, Anson DS, Peake IR, Bloom AL. Heterogeneity of the factor IX locus in nine hemophilia B inhibitor patients. J Clin Invest 1987; 79: 746-53.
70. Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, Miller RT, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Ped Hematol/Onc 1997; 19: 23-7.
71. Green PM, Montandon AJ, Bentley DR, Giannelli F. Genetics and molecular biology of haemophilias A and B. Blood Coagulation & Fibrinolysis 1991; 2: 539-65.